GLP-1 denials (Wegovy, Ozempic, Zepbound): what actually flips them

GLP-1 weight-loss drugs are the most-denied prescription category in U.S. healthcare right now. Wegovy, Zepbound, and Mounjaro lead the pack. The denials look identical across carriers, 'not medically necessary,' 'BMI threshold not met,' 'lifestyle modifications first', but the path to reversal varies.

Three angles work consistently. We use whichever one fits your case.

Angle 1: The T2D pathway. If you have type 2 diabetes (or even prediabetes with elevated A1C), the GLP-1 has a separate coverage track on most plans. Ozempic and Mounjaro are FDA-approved for diabetes; Wegovy and Zepbound for weight loss. If your plan denies the weight-loss indication but covers the diabetes one, switching the prescription path to the molecule's diabetes-approved name is often a 14-day fix.

Angle 2: The medical-necessity letter. Almost no GLP-1 denial cites the actual clinical criteria the carrier used. By law, you can request them in writing. Once you have them, your prescribing doctor writes a letter addressing each criterion specifically, comorbidities, BMI history, prior trial of lifestyle interventions, family history of cardiovascular disease. We draft the letter; the doctor signs it.

Angle 3: The formulary exception. If the drug is non-formulary on your plan (a different category than 'denied'), the manufacturer has clinical justification packets pre-built. Novo Nordisk and Eli Lilly both publish them. Filing a formulary exception with the manufacturer's packet attached is the fastest path on Aetna and several BlueCross variants.

Speed matters. GLP-1 prescriptions usually have a fill window. Carriers know this, drag-out is part of the strategy. Filing within 5 days, with the right angle attached, beats filing in week three with the wrong angle.

If your GLP-1 was denied, send us the letter. We'll tell you within 24 hours which angle fits.